Quest Diagnostics Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Quest Diagnostics Inc trades at $237.64 (market cap $26.21B), while Hilton Hotels Corporation Common Stock trades at $323.91 (market cap $70.82B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 2.7× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | HLT | |
|---|---|---|
Market Cap | $26.21B | $70.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $350.22 |
52-Week Low | $173.49 | $256.75 |
Enterprise Value | $31.97B | $83.83B |
Dividend Yield | 1.45% | 0.19% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Hilton Worldwide Holdings (HLT) trades at $311.00, down 2.08% over 24 hours, amid a bearish technical signal. The stock shows strong fundamentals with Q2 2026 EPS of $2.29 meeting estimates and revenue growth to $12.04 billion in 2025. However, a high P/E of 46.21 and rising debt-to-asset ratio to 73.88% in 2025 highlight valuation and leverage concerns. Recent news includes a 50-day strike at a Seattle hotel and mixed institutional trading activity.
The outlook for HLT is cautiously optimistic, supported by robust travel demand and a record pipeline, but tempered by premium valuation and debt risks. Analysts maintain a buy consensus with a $352.00 price target, suggesting 13% upside. Key risks include labor disputes, soft international demand, and interest rate sensitivity. Investors should weigh growth prospects against financial leverage and market sentiment shifts.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →